Semaglutide and Tirzepatide multidomain outcomes in knee osteoarthritis with obesity evaluated for cost-effectiveness
The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity.
Abstract
A study evaluated multidomain outcomes of semaglutide and tirzepatide for knee osteoarthritis and obesity, including cost-effectiveness.
TitrateLab articles covering Tirzepatide
Written by TitrateLab, separately from the study summarized above.
